Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Assistance Publique - Hôpitaux de Paris |
---|---|
Information provided by: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT00798109 |
Schizophrenia is a severe mental illness with a lifetime morbidity risk close to 1 %, involving both genetic and environmental risk factors. Prospective studies have shown that heavy use of cannabis in adolescence moderately increases the risk of developing schizophrenia. Many data have also suggested that the co-occurrence of cannabis abuse in patients with schizophrenia has a deleterious impact on the clinical outcome of schizophrenia. Cannabis abuse by schizophrenic patients is a significant public health problem for which there is no empirically validated treatment. We are presently studying the efficiency of motivational therapy on cannabis consumption in patients with schizophrenia.
Condition | Intervention |
---|---|
Schizophrenia Cannabis Abuse/Dependence |
Behavioral: Motivational therapy Behavioral: Usual care |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | An Open Multicentric Randomized Clinical Trial Assessing the Impact of Motivational Interviewing on Cannabis Consumption in Patients With Psychiatric Disease |
Estimated Enrollment: | 330 |
Study Start Date: | November 2008 |
Estimated Study Completion Date: | September 2011 |
Estimated Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
Four motivational interview for cannabis abuse in schizophrenia population during one month
|
Behavioral: Motivational therapy
One hour of motivational therapy each weak during 4 weeks
|
B
Usual care with intensive psychotherapy
|
Behavioral: Usual care
Patients received at least six hour of usual therapy, as in the experimental group
|
Schizophrenia is a severe mental illness with a lifetime morbidity risk close to 1 %, involving both genetic and environmental risk factors. Prospective studies have shown that heavy use of cannabis in adolescence moderately increases the risk of developing schizophrenia. Many data have also suggested that the co-occurrence of cannabis abuse in patients with schizophrenia has a deleterious impact on the clinical outcome of schizophrenia. Cannabis abuse by schizophrenic patients is a significant public health problem for which there is no empirically validated treatment. We are presently studying the efficiency of motivational therapy on cannabis consumption in patients with schizophrenia.
330 patients with schizophrenia and cannabis abuse or dependence (according to DSM-IV criteria) are randomly assigned to 4 motivational interview during one month or usual intensive treatment. Treatment is conducted in outpatient which are evaluated at the inclusion and at 6 month with Time-Line Follow Bach for the consumption, PANSS score, number of relapse…). A outcome measure was urinalysis results providing an objective measure of cannabis use throughout the six month of the trial.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
EXCLUSION CRITERIA:
Contact: Caroline DUBERTRET, MD,PhD | 0147606413 | caroline.dubertret@lmr.aphp.fr |
Contact: Lucia Romo, PhD | 0687511271 | lucia.romo@wanadoo.fr |
France | |
Service de psychiatrie (Pr Adès) | Recruiting |
Colombes, France, 92700 | |
Contact: Caroline Dubertret, MD,PhD +33 (0) 1 47 60 64 13 caroline.dubertret@lmr.aphp.fr | |
Contact: Caroline Dubertret, MD,PhD +33 (0) 1 47 60 64 13 caroline.dubertret@lmr.aphp.fr |
Principal Investigator: | Caroline DUBERTRET, MD,PhD | Assistance Publique - Hôpitaux de Paris |
Responsible Party: | Department Clinical Research of Developpement ( Amel Ouslimani ) |
Study ID Numbers: | P 070156, AOM 07007 |
Study First Received: | September 30, 2008 |
Last Updated: | November 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00798109 |
Health Authority: | France: Ministry of Health |
Schizophrenia Cannabis misuse comorbidity Motivational interview Randomised open trial |
Schizophrenia Mental Disorders Substance-Related Disorders Disorders of Environmental Origin |
Psychotic Disorders Marijuana Abuse Schizophrenia and Disorders with Psychotic Features |